Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.

Sun P, Song Y, Liu D, Liu G, Mao X, Dong B, Braicu EI, Sehouli J.

Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.

2.

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Sun P, Mao X, Gao M, Huang M, Chen L, Ruan G, Huang W, Braicu EI, Sehouli J.

Cancer Manag Res. 2018 Aug 10;10:2521-2535. doi: 10.2147/CMAR.S168043. eCollection 2018.

3.

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, Fridrich C, Markmann S, Potenberg J, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J; NOGGO; AGO TRIAS Investigators.

Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.

PMID:
30100379
4.

Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.

Babayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ, Sehouli J.

Int J Gynecol Cancer. 2018 Aug 7. doi: 10.1097/IGC.0000000000001328. [Epub ahead of print]

PMID:
30095708
5.

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.

Parashkevova A, Sehouli J, Richter R, Dimitrova D, Braicu EI, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4865-4870. doi: 10.21873/anticanres.12799.

PMID:
30061261
6.

Morphology and tumor-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Jul 14. doi: 10.1111/his.13711. [Epub ahead of print]

PMID:
30007074
7.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

PMID:
29955134
8.

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP.

Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454. eCollection 2018.

9.

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Müller D, Mentze M, Dechend R, Sehouli J, Braicu EI.

Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.

PMID:
29848718
10.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392
11.

Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Ruscito I, Braicu EI, Gasparri ML, Zizzari IG.

Biomed Res Int. 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019. eCollection 2018. No abstract available.

12.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
13.

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2018 Apr 17;13(4):e0196142. doi: 10.1371/journal.pone.0196142. eCollection 2018.

14.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.

Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5.

15.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

16.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196142.

17.

The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.

Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, Gungor T, Pakay G, Telli EU, Cuylan ZF, Toptas T, Bilgi A, Ozyurt R, Agacayak E, Ozdemir A, Yildirim N, Taskin S, Oge T, Erol O, Akman L, Turan A, Icen MS, Senol T, Ovali OI, Yucesoy B, Gungorduk O, Temizkan O, Sanci M, Simsek T, Meydanli MM, Harma M, Yasar L, Uysal AD, Karateke A, Ortac F, Ozalp SS, Sehouli J, Muallem MZ.

Anticancer Res. 2017 Oct;37(10):5609-5616.

PMID:
28982877
18.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

PMID:
28972047
19.

Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.

PMID:
28691938
20.

Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.

Muallem MZ, Parashkevova A, Almuheimid J, Richter R, Diab Y, Braicu EI, Sehouli J.

Anticancer Res. 2017 Jun;37(6):3157-3161.

PMID:
28551658
21.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

22.

The ascites N-glycome of epithelial ovarian cancer patients.

Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V.

J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001. Epub 2017 Feb 8.

PMID:
28188862
23.

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.

Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A, Timmerman D, Lambrechts D, Vergote I.

Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. Epub 2016 Nov 14.

24.
25.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Castillo-Tong DC, Wisman GBA, Berns EM, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2017 May 1;23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. Epub 2016 Sep 23.

26.

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Dechend R, Muller DN, Sehouli J, Braicu EI.

Anal Cell Pathol (Amst). 2016;2016:6845213. Epub 2016 Aug 31.

27.

Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Muallem MZ, Almuheimid J, Richter R, Braicu EI, Osman S, Sehouli J.

Anticancer Res. 2016 Sep;36(9):4707-13.

PMID:
27630317
28.

Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).

Rohr I, Braicu EI, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR.

Cytokine. 2016 Sep;85:157-64. doi: 10.1016/j.cyto.2016.06.021. Epub 2016 Jun 29.

PMID:
27371774
29.

Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.

Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, Mueller MD, Panici PB, Papadia A.

Ann Surg Oncol. 2016 Oct;23(11):3749-3756. doi: 10.1245/s10434-016-5236-x. Epub 2016 May 9. Review.

PMID:
27160526
30.

Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64].

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jun;60:226. doi: 10.1016/j.ejca.2016.03.007. Epub 2016 Apr 19. No abstract available.

PMID:
27106403
31.

Statistical controversies in clinical research: the importance of importance.

Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.

Ann Oncol. 2016 Jul;27(7):1185-9. doi: 10.1093/annonc/mdw159. Epub 2016 Apr 6.

PMID:
27052655
32.

Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI.

Anticancer Res. 2016 Mar;36(3):1015-22.

PMID:
26976992
33.

PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.

Sehouli J, Braicu EI, Chekerov R.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):164-169. Review.

34.

Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.

Ann Surg Oncol. 2016 Apr;23(4):1279-86. doi: 10.1245/s10434-015-4959-4. Epub 2016 Jan 29.

PMID:
26832880
35.

Acute-phase glycoprotein N-glycome of ovarian cancer patients analyzed by CE-LIF.

Weiz S, Wieczorek M, Schwedler C, Kaup M, Braicu EI, Sehouli J, Tauber R, Blanchard V.

Electrophoresis. 2016 Jun;37(11):1461-7. doi: 10.1002/elps.201500518. Epub 2016 Feb 17.

PMID:
26763099
36.

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.

PMID:
26693899
37.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

38.

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.

Arsenic R, Braicu EI, Letsch A, Dietel M, Sehouli J, Keilholz U, Ochsenreither S.

BMC Cancer. 2015 Oct 24;15:784. doi: 10.1186/s12885-015-1824-6.

39.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
40.

AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.

Muallem MZ, Gasimli K, Richter R, Almuheimid J, Nasser S, Braicu EI, Sehouli J.

Anticancer Res. 2015 Jun;35(6):3423-9.

PMID:
26026105
41.

Surgery at primary versus relapsed epithelial ovarian cancer: a study on aspects of anaesthesiological management.

Feldheiser A, Yosef AB, Braicu EI, Bonomo T, Kaufner L, Spies C, Sehouli J, Fotopoulou C, Pietzner K.

Anticancer Res. 2015 Mar;35(3):1591-601.

PMID:
25750315
42.

Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.

Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J.

Ann Surg Oncol. 2015 Aug;22(8):2729-37. doi: 10.1245/s10434-014-4329-7. Epub 2015 Feb 12.

PMID:
25672560
43.

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.

Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.

Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014.

44.

Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery.

Schwedler C, Kaup M, Weiz S, Hoppe M, Braicu EI, Sehouli J, Hoppe B, Tauber R, Berger M, Blanchard V.

Anal Bioanal Chem. 2014 Nov;406(28):7185-93. doi: 10.1007/s00216-014-8168-y. Epub 2014 Sep 19.

PMID:
25234305
45.

The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.

Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V.

Dis Markers. 2014;2014:238197. doi: 10.1155/2014/238197. Epub 2014 Aug 12.

46.

Polymorphism of the IL-8 gene and the risk of ovarian cancer.

Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M, Goyal P, Evert M, Olek S, Biebler KE, Mustea A.

Cytokine. 2015 Feb;71(2):334-8. doi: 10.1016/j.cyto.2014.07.254. Epub 2014 Aug 21.

PMID:
25151495
47.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.

J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221. Epub 2014 Jul 3.

48.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
49.

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.

Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, Timmerman D, Vergote I, Sehouli J.

J Ovarian Res. 2014 May 7;7:49. doi: 10.1186/1757-2215-7-49. eCollection 2014.

50.

Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients.

Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, Blanchard V.

Electrophoresis. 2014 Apr;35(7):1025-31.

PMID:
24812685

Supplemental Content

Loading ...
Support Center